Carnitine for Heart & Circulation
This is carnitine's strongest area — and it is important to be precise about what "strongest" means. Across several trials in people recovering from a heart attack, living with heart failure, or suffering from angina or peripheral artery disease, adding L-carnitine (or its propionyl form) on top of standard treatment produced measurable benefits: less adverse remodeling of the heart, fewer deaths and arrhythmias in one pooled analysis, and longer pain-free walking distances. But every one of those findings comes with the same three caveats. Carnitine is an adjunct, not a substitute for proven drugs and procedures. The pivotal trials are mostly from the 1990s and 2000s, before today's background therapy. And no large modern outcome trial has confirmed the mortality signal. This page walks through that evidence: what was found, in whom, and what is still unknown.
Interactive Visualization Fat Burning & Ketosis — what actually happens Follow a fatty acid out of a fat cell to the mitochondrial gate and find it padlocked by insulin. Drop the carbs, open CPT1, and watch the liver start making ketones. Launch →
Table of Contents
- Why the Heart Runs on Fat
- Why the Ischemic Heart Becomes Carnitine-Depleted
- After a Heart Attack: The CEDIM Remodeling Trials
- Secondary Prevention: The DiNicolantonio Meta-Analysis
- Chronic Heart Failure & Dilated Cardiomyopathy
- Angina and Ischemic Heart Disease
- Propionyl-L-Carnitine and Peripheral Artery Disease
- The Honest Framing: Adjunct, Older Trials, Missing Evidence
- Practical Considerations, Forms & Safety
- Key Research Papers
- Connections
- Featured Videos
Why the Heart Runs on Fat
The heart is the most metabolically demanding organ in the body per gram, and under normal resting conditions it draws roughly 60–90% of its adenosine triphosphate (ATP) from fatty-acid oxidation. Fat is an energy-dense fuel, but burning it depends entirely on the carnitine shuttle described on the Benefits hub: long-chain fatty acids must be attached to carnitine to cross into the mitochondrion. A heart with adequate carnitine has metabolic flexibility — it can burn fat efficiently and switch to glucose when needed.
That dependence on fat is a strength in a healthy heart and a vulnerability in a sick one. When oxygen delivery falls — during ischemia from a blocked coronary artery, or the chronic low-output state of heart failure — fatty-acid oxidation becomes metabolically expensive because it consumes more oxygen per adenosine triphosphate than glucose does. The stressed heart tries to shift toward glucose, but the machinery for that shift, and the carnitine that governs it, is often depleted at exactly the moment it is most needed. This is the biological rationale behind every cardiac carnitine trial: restore the substrate and you may help the heart manage its own fuel crisis.
Why the Ischemic Heart Becomes Carnitine-Depleted
Healthy adults with a normal diet do not benefit from extra carnitine for their hearts, because cardiac carnitine is already saturated. The failing or ischemic heart is different in a concrete, measurable way: its tissue carnitine content drops.
- Ischemia drains free carnitine. When oxygen is short, incompletely oxidized fatty acids accumulate as long-chain acylcarnitines. Carnitine gets "trapped" in this acylated form, lowering the free carnitine available to shuttle new fatty acids and to buffer acetyl-CoA.
- Accumulated acylcarnitines are themselves harmful. They are detergent-like molecules that can disrupt cell membranes and interfere with ion channels, contributing to the electrical instability (arrhythmias) that makes heart attacks so dangerous in the first hours.
- Failing myocardium down-regulates fat oxidation. Chronic heart failure shifts the heart toward a more "fetal" glucose-dependent metabolic pattern and is associated with reduced myocardial carnitine.
Because carnitine supply is genuinely limiting in these states, restoring it is biologically plausible in a way it simply is not for a healthy person hoping to "boost" an already-normal heart. This distinction — deficient-and-limiting versus already-adequate — is the thread running through every honest carnitine discussion on this site, from fat metabolism to exercise.
After a Heart Attack: The CEDIM Remodeling Trials
The best-known cardiac carnitine research is the CEDIM program (Carnitine Ecocardiografia Digitalizzata Infarto Miocardico). After a large anterior heart attack, the damaged left ventricle often remodels — it dilates and changes shape over weeks to months, and greater dilation predicts worse long-term outcomes. CEDIM asked whether starting L-carnitine early could blunt that dilation.
The original CEDIM trial (Iliceto et al., Journal of the American College of Cardiology, 1995) randomized 472 patients with a first anterior myocardial infarction to L-carnitine (9 g/day intravenously for 5 days, then 6 g/day orally for 12 months) or placebo, started within 24 hours of symptom onset. The carnitine group showed significantly less increase in left-ventricular end-diastolic and end-systolic volumes over the year — in plain terms, the ventricle dilated less. The trial was not powered to prove a mortality benefit, and clinical endpoints (death and heart failure combined) trended favorably without reaching statistical significance on their own.
The larger follow-up, CEDIM-2 (Tarantini et al., Cardiology, 2006), was planned to enroll 4,000 patients with an anterior heart attack but was stopped at 2,330 because enrolment was slower than expected. Its main measure, death or heart failure at 6 months, did not differ significantly (9.2% with L-carnitine versus 10.5% with placebo, p = 0.27). Deaths in the first 5 days, a secondary measure, were lower with L-carnitine (hazard ratio 0.61, 95% confidence interval 0.37–0.98, p = 0.041). So the trial did not deliver a clean, decisive mortality result, and enthusiasm cooled as reperfusion therapy (angioplasty and stenting) transformed heart-attack care and shrank the room for a metabolic adjunct to show effect. The honest read: CEDIM established a plausible surrogate benefit (less remodeling) but never nailed down a hard outcome benefit in the modern-treatment era.
Secondary Prevention: The DiNicolantonio Meta-Analysis
The single most-cited piece of favorable evidence is a 2013 systematic review and meta-analysis by DiNicolantonio and colleagues in Mayo Clinic Proceedings. Pooling 13 controlled trials with about 3,600 participants who had had a heart attack, the authors reported that L-carnitine was associated with a 27% reduction in all-cause mortality, a 65% reduction in ventricular arrhythmias, and a 40% reduction in anginal symptoms compared with placebo or control.
Those are striking numbers, and they are the reason carnitine keeps appearing in cardiology conversations. But they come with real caveats:
- Most of the included trials were small and old, conducted before or during the transition to modern reperfusion, high-intensity statins, dual antiplatelet therapy, and current heart-failure drugs. A benefit layered on 1980s–90s care may shrink or vanish on top of 2020s care.
- Meta-analyses of many small trials are vulnerable to publication bias and heterogeneity; the authors themselves called for a large modern randomized trial to confirm the signal.
- That confirmatory mega-trial has not been done. More than a decade later, the mortality claim remains unconfirmed by a single large, contemporary, adequately powered study.
So the correct summary is: a meta-analysis of older trials suggests a meaningful benefit after heart attack, but it is hypothesis-generating, not practice-defining. In these trials carnitine was given on top of standard therapy, not in place of it.
Chronic Heart Failure & Dilated Cardiomyopathy
Several trials have examined carnitine (usually L-carnitine or propionyl-L-carnitine) as an add-on in chronic heart failure. The most frequently cited is Rizos (American Heart Journal, 2000), a small controlled study of 80 patients with moderate to severe heart failure (New York Heart Association class III–IV) from dilated cardiomyopathy. Patients receiving L-carnitine (2 g/day) added to conventional therapy had markedly better survival than the placebo group: after a mean of 33.7 months there was 1 death in the L-carnitine group versus 6 in the placebo group (P < .04). The result is encouraging but comes from a small trial, and small survival trials are notoriously prone to overstating effects.
The 1999 multicenter "Study on propionyl-L-carnitine in chronic heart failure" (European Heart Journal) tested propionyl-L-carnitine in a larger population. Among 537 patients (271 on propionyl-L-carnitine, 266 on placebo) it did not show an overall benefit on the primary endpoint, maximal exercise time. A subgroup chosen after the fact — patients with an ejection fraction of 30–40% — improved maximal exercise time by 40 seconds, while the subgroup planned in advance (by baseline exercise time) showed only a trend; the authors called this an exploratory hypothesis that needs its own trial — a classic "positive subgroup in an overall-negative trial" result.
Meta-analyses of carnitine in heart failure (including recent 2020s pooled analyses) generally report modest improvements in ejection fraction, exercise tolerance, and symptom scores, while consistently noting that the underlying trials are small, heterogeneous, and of limited quality. A 2017 meta-analysis of 17 randomized trials with 1,625 patients, for example, found that L-carnitine raised left-ventricular ejection fraction by 4.14 percentage points and lowered the heart-strain blood markers B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), but found no significant difference in all-cause mortality, 6-minute walk distance or side effects (Song 2017). The pattern is remarkably stable across two decades: signals of benefit, never definitive proof. Carnitine is not part of any major guideline-directed heart-failure regimen, which today centers on the "four pillars" of angiotensin receptor-neprilysin inhibitors (ARNI)/angiotensin-converting enzyme inhibitors (ACE-inhibitors), beta-blockers, mineralocorticoid-receptor antagonists, and sodium-glucose cotransporter-2 (SGLT2) inhibitors.
Angina and Ischemic Heart Disease
Angina — chest pain from a heart muscle starved of oxygen — is the setting where carnitine's metabolic logic is most intuitive. By improving the ischemic heart's ability to manage fuel and clear toxic acylcarnitines, carnitine might raise the threshold at which exertion provokes pain. Older controlled trials of L-carnitine and propionyl-L-carnitine in stable angina reported improvements in exercise tolerance, time to ST-segment depression on treadmill testing, and reduced nitroglycerin use.
Ferrari and colleagues reviewed this literature in Annals of the New York Academy of Sciences (2004), concluding that carnitine and propionyl-L-carnitine have a plausible anti-ischemic role as metabolic agents, in the same conceptual family as trimetazidine and ranolazine (drugs that shift cardiac metabolism toward glucose). The reduction in anginal symptoms was also a component of the DiNicolantonio meta-analysis discussed above. As with every cardiac application, the trials predate modern anti-anginal therapy and revascularization, so the incremental benefit today is uncertain.
Propionyl-L-Carnitine and Peripheral Artery Disease
Peripheral artery disease (PAD) causes intermittent claudication — cramping leg pain during walking that forces the person to stop and rest, because narrowed arteries cannot supply the exercising muscle. Ischemic leg muscle, like ischemic heart muscle, accumulates acylcarnitines and loses metabolic efficiency, which is why the propionyl-L-carnitine form (which delivers both carnitine and a readily oxidized propionyl group into the Krebs cycle) has been studied specifically here.
A 2013 systematic review and meta-analysis in Vascular Medicine found that propionyl-L-carnitine modestly increased both pain-free and maximal walking distance versus placebo in people with claudication. A 2021 Cochrane review (12 studies, 1,423 participants) rated the overall certainty of the evidence as moderate: compared with placebo, propionyl-L-carnitine increased maximal walking distance by about 51 meters (26%) and pain-free walking distance by about 33 meters (31%), an improvement it called mild to moderate, with similar safety. It also noted high heterogeneity between studies and a high proportion of drug-company-backed studies. Supervised exercise therapy and standard peripheral artery disease medical management (statins, antiplatelet therapy, smoking cessation, and cilostazol where appropriate) remain the evidence-based foundation. The Cochrane authors found no randomized trial comparing propionyl-L-carnitine with standard treatment.
The Honest Framing: Adjunct, Older Trials, Missing Evidence
If you take one thing from this page, take these three sentences. First, carnitine in cardiovascular disease is always an adjunct — something added on top of guideline-directed therapy, never a replacement for statins, antiplatelets, revascularization, or the four pillars of heart-failure treatment. Second, the favorable evidence rests heavily on trials from the 1990s and 2000s, conducted before the background of care reached its current strength, which likely inflates the apparent incremental benefit. Third, the one thing that would settle the question — a large, modern, adequately powered outcome trial — has never been performed, and probably never will be, because there is no patent incentive to fund it.
This does not make carnitine useless. It makes it a reasonable, low-risk, physician-supervised adjunct with a plausible mechanism and suggestive data, whose true modern benefit is genuinely unknown. Anyone who tells you carnitine "cures" heart failure or "prevents heart attacks" is overselling. Anyone who dismisses it as pure snake oil is ignoring the remodeling and meta-analysis data. The truth lives in the honest middle.
Practical Considerations, Forms & Safety
- Forms. Cardiac trials used plain L-carnitine (often 2–6 g/day) or propionyl-L-carnitine (favored for angina and peripheral artery disease because the propionyl group feeds the Krebs cycle directly). Acetyl-L-carnitine is oriented toward the brain and nerves, not the heart — see Forms & the trimethylamine N-oxide (TMAO) Question.
- Typical doses in trials. 2–6 g/day of L-carnitine, split into two or three doses. This is a research context, not a self-prescribing recommendation.
- Safety. Oral L-carnitine is generally well tolerated; the most common effects are nausea, cramping, diarrhea, and a fishy body odor at higher doses (from trimethylamine). It is cleared by the kidneys, which matters for people with kidney disease.
- The trimethylamine N-oxide wrinkle. The same gut bacteria that make some people produce more trimethylamine N-oxide from carnitine (a compound linked to atherosclerosis) create a genuine theoretical tension with the cardiovascular-benefit trials. This "carnitine paradox" is unresolved and is covered in full on the Forms & trimethylamine N-oxide page.
- Who it has been studied in. People with heart failure, refractory angina, claudication, or documented carnitine deficiency (including dialysis patients) — in the trials, always on top of their proven therapy, never instead of it.
- Dialysis and the heart. In people on hemodialysis, a 2025 meta-analysis (7 studies, 426 patients) found that L-carnitine raised left-ventricular ejection fraction slightly (by 1.64 points, p = 0.04) but did not significantly change heart-muscle mass (left ventricular mass index) or diastolic (filling) function (Nabi 2025).
- Interactions. L-carnitine blocks some actions of thyroid hormone in the body: a 2001 randomized trial in 50 women taking levothyroxine at thyroid-suppressing doses used 2 or 4 g a day of L-carnitine to reverse and prevent symptoms of excess thyroid hormone (Benvenga 2001), so it can blunt the effect of thyroid hormone. Case reports describe a stronger blood-thinning effect of the vitamin K antagonist acenocoumarol after L-carnitine was added (Martinez 1993; Bachmann 2004).
This page is educational. Cardiovascular disease is dangerous, and every trial above tested carnitine only alongside standard heart treatment.
Key Research Papers
- DiNicolantonio JJ, Lavie CJ, Fares H, Menezes AR, O'Keefe JH (2013). L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis. Mayo Clinic Proceedings. — PubMed PMID: 23597877
- Iliceto S et al. (1995). Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the CEDIM trial. Journal of the American College of Cardiology. — PubMed PMID: 7608438
- Colonna P, Iliceto S (2000). Myocardial infarction and left ventricular remodeling: results of the CEDIM trial. Carnitine Ecocardiografia Digitalizzata Infarto Miocardico. American Heart Journal. — PubMed PMID: 10650326
- Rizos I (2000). Three-year survival of patients with heart failure caused by dilated cardiomyopathy and L-carnitine administration. American Heart Journal. — PubMed PMID: 10650325
- Study Group (1999). Study on propionyl-L-carnitine in chronic heart failure. European Heart Journal. — PubMed PMID: 10075143
- Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C (2004). Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Annals of the New York Academy of Sciences. — PubMed PMID: 15591005
- Kamoen V, Vander Stichele R, Campens L, De Bacquer D, Van Bortel L, de Backer TL (2021). Propionyl-L-carnitine for intermittent claudication. Cochrane Database of Systematic Reviews. — PubMed PMID: 34954832
- Brass EP, Koster D, Hiatt WR, Amato A (2013). A systematic review and meta-analysis of propionyl-L-carnitine effects on exercise performance in patients with claudication. Vascular Medicine. — PubMed PMID: 23321261
- Tarantini G, Scrutinio D, Bruzzi P, Boni L, Rizzon P, Iliceto S (2006). Metabolic treatment with L-carnitine in acute anterior ST segment elevation myocardial infarction. A randomized controlled trial. Cardiology. — PubMed PMID: 16685128
- Song X, Qu H, Yang Z, Rong J, Cai W, Zhou H (2017). Efficacy and Safety of L-Carnitine Treatment for Chronic Heart Failure: A Meta-Analysis of Randomized Controlled Trials. BioMed Research International. — PubMed PMID: 28497060
- Nabi R, Farooqi HA, Abbasi SUAM, et al. (2025). Safety and efficacy of L-carnitine supplementation in improving cardiac function of hemodialysis patients: a systematic review and meta-analysis. International Urology and Nephrology. — PubMed PMID: 40172612
- Benvenga S, Ruggeri RM, Russo A, Lapa D, Campenni A, Trimarchi F (2001). Usefulness of L-carnitine, a naturally occurring peripheral antagonist of thyroid hormone action, in iatrogenic hyperthyroidism: a randomized, double-blind, placebo-controlled clinical trial. Journal of Clinical Endocrinology and Metabolism. — PubMed PMID: 11502782
- Martinez E, Domingo P, Roca-Cusachs A (1993). Potentiation of acenocoumarol action by L-carnitine. Journal of Internal Medicine. — PubMed PMID: 8429297
- Bachmann HU, Hoffmann A (2004). Interaction of food supplement L-carnitine with oral anticoagulant acenocoumarol. Swiss Medical Weekly. — PubMed PMID: 15340883
PubMed Topic Searches
External Resources
Connections
- All Amino Acids
- Fat Burning & Ketosis — interactive animation
- Carnitine Benefits Hub
- Carnitine (Main Page)
- Forms & the Trimethylamine N-Oxide Question
- Exercise & Recovery
- Cardiology
- Heart Failure
- Angina
- Heart Attack
- Coronary Artery Disease
- Peripheral Artery Disease
- Cardiomyopathy
- Atherosclerosis
- Taurine
- Magnesium
- Exercise
- Deficiency